Meeting
2017 ASCO Annual Meeting
Early TKI-pharmokinetics and circulating tumor DNA (ctDNA) to predict outcome in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
Authors
Frederic Bigot
Department of Medical Oncology, Paris Descartes University, Hopital Européen Georges Pompidou, AP-HP, Paris, France
Frederic Bigot , Nicolas Pecuchet , Benoit Blanchet , Pierre Laurent-Puig , Helene Blons , Francois Goldwasser , Pascaline Boudou-Rouquette , Edouard Auclin , Stephane Oudard , Elizabeth Fabre
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Circulating Biomarkers
Citation
J Clin Oncol 35, 2017 (suppl; abstr 11544)
DOI
10.1200/JCO.2017.35.15_suppl.11544
Abstract #
11544
Poster Bd #
244
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Phase Ib study of tepotinib in EGFR-mutant/c-Met-positive NSCLC: Final data and long-term responders.
First Author: Yi-Long Wu
Poster
2016 ASCO Annual Meeting
Phase (Ph) II safety and efficacy results of a single-arm ph ib/II study of capmatinib (INC280) + gefitinib in patients (pts) with EGFR-mutated (mut), cMET-positive (cMET+) non-small cell lung cancer (NSCLC).
First Author: Yi-Long Wu
Poster
2017 ASCO Annual Meeting
Trastuzumab and paclitaxel in patients (pts) with EGFR mutated non-small-cell lung cancer (NSCLC) that express HER2 after progression on EGFR TKI treatment.
First Author: Joop De Langen
Poster
2014 ASCO Annual Meeting
Safety and efficacy of INC280 in combination with gefitinib (gef) in patients with EGFR-mutated (mut), MET-positive NSCLC: A single-arm phase lb/ll study.
First Author: Yi-Long Wu